Artiva Biotherapeutics (NASDAQ:ARTV) Rating Reiterated by Needham & Company LLC

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “buy” rating reissued by analysts at Needham & Company LLC in a report released on Friday, Benzinga reports. They presently have a $23.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 105.91% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the company. TD Cowen began coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set a “buy” rating on the stock. Wedbush began coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They set an “outperform” rating and a $18.00 price objective on the stock. Jefferies Financial Group started coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued a “buy” rating and a $21.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on shares of Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $23.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Artiva Biotherapeutics currently has an average rating of “Buy” and a consensus target price of $21.25.

Artiva Biotherapeutics Trading Down 1.2 %

Shares of Artiva Biotherapeutics stock traded down $0.13 on Friday, reaching $11.17. 31,011 shares of the stock were exchanged, compared to its average volume of 114,684. Artiva Biotherapeutics has a 1-year low of $9.71 and a 1-year high of $16.00.

Insider Transactions at Artiva Biotherapeutics

In other news, major shareholder Global Strategic Fund I. Venbio acquired 416,666 shares of the company’s stock in a transaction that occurred on Monday, July 22nd. The stock was purchased at an average cost of $12.00 per share, with a total value of $4,999,992.00. Following the purchase, the insider now directly owns 1,936,637 shares of the company’s stock, valued at approximately $23,239,644. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Artiva Biotherapeutics news, Director Yong-Jun Huh purchased 2,083,332 shares of the stock in a transaction dated Monday, July 22nd. The shares were acquired at an average cost of $12.00 per share, for a total transaction of $24,999,984.00. Following the completion of the transaction, the director now directly owns 3,306,900 shares of the company’s stock, valued at $39,682,800. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Global Strategic Fund I. Venbio acquired 416,666 shares of the company’s stock in a transaction dated Monday, July 22nd. The shares were acquired at an average cost of $12.00 per share, with a total value of $4,999,992.00. Following the completion of the purchase, the insider now owns 1,936,637 shares in the company, valued at $23,239,644. The disclosure for this purchase can be found here.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.